Anemia Treatment Gains Reliable Protection Against Needlestick Injuries for Caregivers
Schreiner MediPharm Equips Syringes for Pfizer Epoetin Product with Its Needle-Trap Solution
Pfizer, one of the world's largest pharmaceutical companies, develops innovative medicines and vaccines as well as some of the most popular over-the-counter products. In search of a reliable solution to protect healthcare personnel from needlestick injuries when injecting the company’s epoetin product for the treatment of anemia, Pfizer chose Schreiner MediPharm's Needle-Trap. Pfizer has been using this innovative label-based needle protection system on millions of syringes for a heparin drug since 2009.
Needle-Trap features a unique design: The plastic needle trap is an integral component of the label for prefilled syringes, and serves to secure the needle after the injection has been performed. Due to its special design, it can be easily integrated into existing pharmaceutical manufacturing processes. Only minor modifications of the finishing and application equipment are needed, and there is no need for adaptation of secondary packaging. Minimal space during shipping, storage and disposal are required.
Schreiner MediPharm’s Needle-Trap meets the requirements of EU Directive 2010/32/EU, U.S. NIOSH for safe instruments and DIN EN ISO 23908 for sharps injury protection. In addition, it has been cleared by an FDA 510(k) Premarket Notification in the United States.
A cost-effective alternative for prefilled syringes, Needle-Trap is intuitive due to its special design. It features simple and irreversible activation, and requires no changes to the user’s injection technique, as the needle protection is integrated into the syringe label.
More than 10,000 research scientists and some 97,000 employees at Pfizer develop, produce and sell innovative medicines and vaccines as well as some of the world’s best known over-the-counter products. In Germany, Pfizer currently employs roughly 2,500 people at three locations: Berlin, Freiburg and Karlsruhe. Biosimilars, which are generic biopharmaceuticals, represent an important field for Pfizer in the future. The company consistently invests in their research and development. As an economic alternative, biosimilars make it possible for more patients to access a broader range of therapies.
For further information, contact:
Schreiner MediPharm, a business unit of
Schreiner Group LP
300 Corporate Drive, Suite 10
Blauvelt, NY 10913
Phone (845) 848-9000
Fax (845) 848-9041